Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced it has been added to the broad-market Russell 3000^® Index and the Russell 2000^® Index, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution.

Read more at globenewswire.com